PIK3CA and neoplasm: Clinical benefits from the EGFR inhibitor (94) and a pan-PI3K inhibitor (95) have been reported in TNBC patients, while Fu et al. (96) further reported that EGFR/Notch bispecific antibody PTG12 in combination with pan-PI3K inhibitor GDC-0941 exerted a stronger antitumor effect in TNBC tumors by inhibiting the stem cell–like subpopulation and reducing tumor-initiating cell frequency (Figure 2, Table 2).